Androgenic Brussels sprout plants were produced by the use of anther culture from the donor cultivar 'Philemon F1'. A total of 96 plants obtained from 20 androgenic R0 genotypes assigned as diploids were evaluated both in the generative and vegetative stage, in respect of their morphological characters: mean plant height; leaf size, colour and waxiness; leaf blade shape, blistering and attitude; number of sprouts; as well as their self-incompatibility and fertility. Androgenic R0 plants derived from each of the 20 embryos were highly diversified and differed from the donor in one or more morphological traits in the vegetative stage. Evaluated populations also varied in fertility and self-incompatibility. Six androgenic genotypes that set a sufficient amount of seeds of the R1 generation and 'Philemon F1' were evaluated in the field in respect of plant height, total and marketable yield per plot, shape of stem with sprouts, shape and density of sprouts, and spacing between sprouts. Only four diploid R0 and R1 populations may have some value for further breeding, as they are characterised by good vigour, high or medium ability for sprout generation, and sufficient fertility.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
November 2024
Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
Background: The 2 × 2 PEACE-1 study showed that combining androgen-deprivation therapy with docetaxel and abiraterone improved overall and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. We aimed to examine the efficacy and safety of adding radiotherapy in this population.
Methods: We conducted an open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Europe.
Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Front Med (Lausanne)
October 2024
Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, treatment optimization to further delay disease progression and improve overall survival remains an unmet need. Despite the number of agents with differing MoAs approved for advanced prostate cancer, many patients receive only one or two life-prolonging therapies.
View Article and Find Full Text PDFDarolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.
Cancer Med
November 2024
Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
Article Synopsis
- Darolutamide combined with androgen-deprivation therapy (ADT) and docetaxel significantly lowered the risk of death by 32.5% in the ARASENS study, indicating its effectiveness for treating metastatic hormone-sensitive prostate cancer (mHSPC).
- In the Japanese subgroup analysis of 148 patients, higher percentages of participants were older (≥75 years) and had lower body mass indexes compared to the overall study population, but the treatment showed a similar safety and efficacy profile.
- While overall survival trends were positive for darolutamide in Japanese patients, the combined treatment was well tolerated, with no new safety concerns identified, despite some patients experiencing more frequent adverse events like neutropenia.
Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer.
Eur Urol Oncol
November 2024
Department of Radiology and Medical Imaging, Institut du Cancer Roi Albert II/Institut de Recherche Expérimentale & Clinique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium. Electronic address:
Background And Objectives: We assessed the agreement between prostate-specific antigen (PSA) and imaging responses using whole-body magnetic resonance imaging (wbMRI). Our aim was to explore the potential prognostic value of PSA and wbMRI responses in metastatic hormone-naïve prostate cancer (mHNPC) and castration-resistant PC (mCRPC).
Methods: wbMRI was prospectively performed in 37 patients with mHNPC and 51 with mCRPC before and after 6-12 mo of androgen deprivation therapy and an androgen receptor pathway inhibitor (ARPI).
Oncostatin M: friend or foe in PCOS pathogenesis?
J Endocrinol
December 2024
Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Article Synopsis
- Polycystic ovary syndrome (PCOS) is a condition that affects women and causes problems like hormonal imbalance and irregular periods.
- It can lead to issues like obesity, diabetes, and inflammation, which can mess with how the body works.
- Researchers are studying a protein called oncostatin M (OSM) to see how it might be connected to these problems in PCOS, but more research is needed to understand its role and if it could help in treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!